News
Apillet has been granted its first national patents
Company announcement No 06/2023.
Roskilde, September 27. 2023
We are thrilled to announce the decission by the European Patent Office to grant Apillet a European Patent with the title Novel Oral Composition. The decision will take effect on October 4. 2023, when the mention of the grant is published in the European Patent Bulletin 23/40.
We are happy that the IP rights for Apillets groundbreaking encapsulation technology behind our APIVault and NeutraValt lines of gastro-resistant enteric encapsulation for biopharmaceuticals and nutraceuticals are now starting to be secured on national levels.
Apillet participates in FBHC 2023
Company announcement No 05/2023.
Roskilde, September 19. 2023
Apillet participates in FBHC 2023 – 4th International Conference on Food Bioactives & Health.
CEO Anders Christensen is participating in FBHC 2023 September 18-21 in Prague and promoting our gastro-resistant enteric encapsulation technologies looking for investors / financing, for clients and partners and for R&D collaborations and partnerships. Please get in touch if you would like to schedule a meeting with Apillet.
CEO Anders B. Christensen, cell +45 5178 0684, email: anders.christensenapillet.com
Apillet has identified the first intestinal delivery targets for the APIVault encapsulation.
Company announcement No 04/2023.
Roskilde, May 19. 2023
Apillet ApS today announces the first intestinal delivery targets for its APIVault enteric encapsulation material for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals.
APIVault is a breakthrough encapsulation material made entirely from natural ingredients: bacterial cellulose and cellulases. We have conducted rigorous laboratory tests and numerical simulations to map the release properties of the combo-material in the intestine. Our results demonstrate that APIVault can deliver compounds reliably in the late small intestine and the colon, using the most suitable cellulases available in the market.
Apillet is currently defining additional development work and is actively looking for additional investments or pharma collaborations for the development of APIVault.
The release properties of Apillets combo-material APIVault shows a high degree of reproducibility.
Company announcement No 03/2023.
Roskilde, April 28. 2023
Apillet has further studied the design factors that governs the release onset of the APIVault encapsulation.
Apillet ApS, a Danish biotech company, develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals, today announces the results of studies of the design factors that governs the release onset of its APIVault encapsulation material. The APIVault encapsulation material is produced solely from natural materials with a combination of bacterial cellulose and cellulases.
We are thrilled to share our findings on the design factors of the combo material controlling the release of encapsulated material. We have conducted systematic studies on how these factors affect the release properties and found that the feature of the material is remarkably consistent. The release mechanism is based on a percolation process. This means that we can achieve a low and controlled leakage before percolation and a rapid release after percolation. We are very happy to share this remarkable result that opens new possibilities for applications of the APIVault technology.
Apillet is currently defining additional development work and is actively looking for additional investments or pharma collaborations for the development of APIVault.
Apillet has identified a commercially available cellulase for its APIVault encapsulation.
Company announcement No 02/2023.
Roskilde, April 11. 2023
Apillet ApS, a Danish biotech company, develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals, today announces the identification of a commercially available cellulase for its APIVault encapsulation material.
We are thrilled to announce that we have found a cellulase enzyme that meets our criteria for the APIVault encapsulation technology. Such a cellulase is crucial for creating the APIVault two-component material that can release drugs or other substances at specific locations in the gastrointestinal tract. The enzyme can degrade cellulose, which is the main component of our APIVault material, in a controlled manner. This allows us to tailor the release profile of our encapsulations according to the needs of different applications. Whether it is for delivering biopharmaceuticals, sensitive pharmaceuticals, probiotics, or nutraceuticals, the APIVault technology offers a natural and effective solution that protects the active ingredients from the harsh environment of the stomach and delivers them where they are most needed. The cellulase comes from a reputable commercial vendor. We are excited about this breakthrough and look forward to sharing more details about our APIVault technology soon.
Apillet is currently defining continued development work and is actively looking for additional investments or pharma collaborations for the development of APIVault.
About APILLET ApS
Apillet ApS is a biotech company based in Roskilde Denmark, that develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals.
Further information:
CEO Anders B. Christensen, cell +45 5178 0684, email: anders.christensenapillet.com
CFO Carsten L. Petersen, cell +45 2346 2718, email: carsten.petersenapillet.com
Apillet has identified Commercially available Bacterial celluloses for our BC-Combo-material
Company announcement
No 01/2023.
Roskilde, March 16. 2023
Apillet ApS, a Danish biotech company, develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals, today announces the identification of Commercially available bacterial cellulose for its APIVault encapsulation material.
The APIVault encapsulation material is produced solely from natural materials with a combination of bacterial cellulose and cellulases. The commercially available bacterial cellulose meets the requirements for the APIVault encapsulation. The encapsulation can be programmed to release the substance at a predetermined location in the small intestine or in the colon.
Apillet has determined properties of Bacterial cellulose from commercial vendors. We have identified several vendors capable of consistently delivering the appropriate quality of Bacterial cellulose. Furthermore, the passive diffusion across bacterial cellulose is very limited under gastrointestinal conditions, showing that bacterial cellulose is an excellent constituent of the 2-combo material.
Apillet is currently defining additional development work and is actively looking for additional investments or pharma collaborations for the development of APIVault.
About APILLET ApS
Apillet ApS is a biotech company based in Roskilde Denmark, that develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals.
Further information:
CEO Anders B. Christensen, cell +45 5178 0684, email: anders.christensenapillet.com
CFO Carsten L. Petersen, cell +45 2346 2718, email carsten.petersenapillet.com
Apillet participated in the 14th International Conference and Exhibition on Nutraceuticals and Functional Foods – October 02 – 05, 2022 – Istanbul
Roskilde October 5, 2022
CEO Anders Christesen presented the talk
“The development of an enteric capsule made from natural materials for oral delivery of Probiotics / Nutraceuticals”
at the 14th International Conference and Exhibition on Nutraceuticals and Functional Foods – October 02 – 05, 2022 – Istanbul.
Apillet ApS Announces in-vitro testing of APIVault tablet Prototype.
Company announcement No. 01/2022
Roskilde, 10.06.2022
Apillet ApS Announces the in-vitro testing of APIVault tablet Prototype.
Apillet ApS, a Danish biotech company, develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals, today announces the first prototype of the APIVault enteric technology for targeted delivery in the small intestine and the colon.
The APIVault encapsulation material is produced solely from natural materials with a combination of bacterial cellulose and cellulases as basis. The prototype is a tablet protecting the enclosed substance against enzymatic degradation and low pH in the stomach. The tablets can be programmed to release the substance at a predetermined location in the small intestine or in the colon.
Apillet has through recent development work obtained further knowledge of the protection properties, release properties and design parameters of APIVault. A formula for targeted release at locations in the small intestine and the colon has been designed. Furthermore, prototypes have been produced.
We are now testing the release properties of a model substance to further validate the APIVault. We are looking for first candidate Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics or Nutraceuticals to test release properties in-vitro and in-vivo.
About APILLET ApS
Apillet ApS, (CVR-no. 41388285) is a biotech company based in Roskilde Denmark, that develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals.
Further information:
CEO Anders B. Christensen, cell +45 5178 0684, email: anders.christensenapillet.com
CFO Carsten L. Petersen, cell +45 2346 2718, email: carsten.petersenapillet.com
Apillet ApS
Ternevej 45
4000 Roskilde, Denmark
CVR. 39601230
Advisor
Virkon ApS
Gammel Kongevej 11
1610 København
Danmark
Skype ID: virkon.dk
virkon@virkon.dk
CVR: 33507798
New data on APIVaults release functionality
Roskilde October 21. 2021
The encapsulation retains the payload until a well-defined percentage of the BC membrane has been digested by the cellulase. When this digestion threshold has been reached there is a sudden change in permeability and the payload is fully released over a short span of time. This release pattern can be explained by a phenomenon known in materials science as percolation. New in vitro data defines narrow boundaries on the percolation threshold of the BC membrane.
The release pattern provides excellent opportunities for controlling the entestinal site of release together with opportunities for controlling the time window for release.
This substantiates that the ApiVault Technology can deliver targeted release of probiotics, prebiotics, nutraceuticals, enzymes, biologics, peptides and small molecules in predestined segments of the intestine.
Apillet to participate in BIOTECHGATE DIGITAL PARTNERING:
Roskilde April 15. 2021
Apillet will attend the international partnering-event BIOTECHGATE DIGITAL PARTNERING May 3 – 7, 2021 that gathers decision-makers from the industry. We are looking for an investor / financing, for clients and partners and for R&D collaborations and partnerships. Please get in touch if you would like to schedule a meeting with Apillet.